Matinas Biopharma Holdings Inc [MTNB] stock is trading at $0.37, up 36.46%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MTNB shares have gain 33.02% over the last week, with a monthly amount glided 32.02%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, March 2024, Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update. In a post published today on Yahoo Finance, Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions.
From an analyst’s perspective:
Matinas Biopharma Holdings Inc [AMEX: MTNB] stock has seen the most recent analyst activity on May 11, 2021, when Piper Sandler downgraded its rating to a Neutral. On January 27, 2020, Piper Sandler initiated with a Overweight rating and assigned a price target of $3 on the stock. SunTrust started tracking the stock assigning a Buy rating. SunTrust initiated its recommendation with a Buy. Aegis Capital started tracking with a Buy rating for this stock on January 09, 2020, and assigned it a price target of $3.50. In a note dated June 26, 2019, H.C. Wainwright initiated an Buy rating and provided a target price of $4 on this stock.
Matinas Biopharma Holdings Inc [MTNB] stock has fluctuated between $0.11 and $0.89 over the past year. Matinas Biopharma Holdings Inc [AMEX: MTNB] shares were valued at $0.37 at the most recent close of the market.
Analyzing the MTNB fundamentals
Matinas Biopharma Holdings Inc [AMEX:MTNB] reported sales of 1.10M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.14% with Operating Profit Margin at -21.68%, Pretax Profit Margin comes in at -20.93%, and Net Profit Margin reading is -20.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.89 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2966 points at the first support level, and at 0.2234 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.4064, and for the 2nd resistance point, it is at 0.4430.
Matinas Biopharma Holdings Inc [MTNB] reported earnings per share of -$0.02 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.03/share, meaning a difference of $0.01 and a surprise factor of 33.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.03 per share as compared to estimates of -$0.03 per share, a difference of $0 representing a surprise of 0.00%.
Ratios To Look Out For
For context, Matinas Biopharma Holdings Inc’s Current Ratio is 5.93. As well, the Quick Ratio is 5.93, while the Cash Ratio is 1.84. Considering the valuation of this stock, the price to sales ratio is 73.11, the price to book ratio is 4.17.
